Praxis Precision Medicines Balance Sheet Health
Financial Health criteria checks 6/6
Praxis Precision Medicines has a total shareholder equity of $382.7M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $416.3M and $33.6M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$357.03m |
| Equity | US$382.67m |
| Total liabilities | US$33.59m |
| Total assets | US$416.26m |
Recent financial health updates
We're Hopeful That Praxis Precision Medicines (NASDAQ:PRAX) Will Use Its Cash Wisely
Aug 30
Companies Like Praxis Precision Medicines (NASDAQ:PRAX) Are In A Position To Invest In Growth
May 14Here's Why Praxis Precision Medicines (NASDAQ:PRAX) Must Use Its Cash Wisely
Nov 29Can Praxis Precision Medicines (NASDAQ:PRAX) Afford To Invest In Growth?
Aug 14Can Praxis Precision Medicines (NASDAQ:PRAX) Afford To Invest In Growth?
Feb 10Here's Why Praxis Precision Medicines (NASDAQ:PRAX) Must Use Its Cash Wisely
Oct 21Recent updates
Praxis Precision Medicines: Great Price Movement, But Still Not Convinced
Oct 13We're Hopeful That Praxis Precision Medicines (NASDAQ:PRAX) Will Use Its Cash Wisely
Aug 30Companies Like Praxis Precision Medicines (NASDAQ:PRAX) Are In A Position To Invest In Growth
May 14Praxis: 2nd Half 2024 ET Readout Could Lead To U.S. Regulatory Filing
Mar 26Is There An Opportunity With Praxis Precision Medicines, Inc.'s (NASDAQ:PRAX) 26% Undervaluation?
Feb 27Here's Why Praxis Precision Medicines (NASDAQ:PRAX) Must Use Its Cash Wisely
Nov 29Can Praxis Precision Medicines (NASDAQ:PRAX) Afford To Invest In Growth?
Aug 14Can Praxis Precision Medicines (NASDAQ:PRAX) Afford To Invest In Growth?
Feb 10Here's Why Praxis Precision Medicines (NASDAQ:PRAX) Must Use Its Cash Wisely
Oct 21Praxis Precision Medicines GAAP EPS of -$1.32 misses by $0.02
Aug 08Praxis: MDD Trial Failure May Not Mean An End To Entire Pipeline
Jun 10We're Keeping An Eye On Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Rate
May 15Companies Like Praxis Precision Medicines (NASDAQ:PRAX) Are In A Position To Invest In Growth
Jan 27Praxis Precision Medicines: Genetic Medicines For Neurological Disease
Nov 23We're Not Very Worried About Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Rate
Oct 14Praxis' PRAX-562 wins Orphan Drug designation for rare encephalopathy
Apr 30Companies Like Praxis Precision Medicines (NASDAQ:PRAX) Are In A Position To Invest In Growth
Mar 12Read This Before Selling Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares
Jan 18Praxis Precision's pediatric epilepsy therapies nab Rare Pediatric and Orphan Drug tags in U.S.
Jan 07Praxis Precision Medicine plummets 27% on clinical hold on lead drug
Nov 10Financial Position Analysis
Short Term Liabilities: PRAX's short term assets ($360.0M) exceed its short term liabilities ($32.9M).
Long Term Liabilities: PRAX's short term assets ($360.0M) exceed its long term liabilities ($729.0K).
Debt to Equity History and Analysis
Debt Level: PRAX is debt free.
Reducing Debt: PRAX has no debt compared to 5 years ago when its debt to equity ratio was 3.2%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PRAX has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: PRAX has sufficient cash runway for 2.9 years if free cash flow continues to reduce at historical rates of 20.6% each year.